Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05359263 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

Study acronym: DECODE-CKD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 10, 2025 (before its estimated February 18, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 9 to 11v5
  2. Primary and study completion dates: Apr 15, 2025 to Feb 18, 2025
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints: 46 to 9
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 15, 2022 to Jun 8, 2022
    v3
  4. Secondary endpoints: 5 to 46
    • Study title shortened, about 2 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate the effects of dapagliflozin on echocardiographic measures of cardiac structure and function in patients with chronic kidney disease.
Trial Details
NCT Number NCT05359263
Lead Sponsor Tor Biering-Sørensen
Conditions
(from sponsor)		 Chronic Kidney Diseases
Related terms Renal Insufficiency, Chronic
Enrollment 222 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov